|Articles|July 27, 2016

Exclusive Coverage of the American Society of Clinical Oncology Annual Meeting 2016 Chicago, Illinoi

Exclusive Coverage of the American Society of Clinical Oncology Annual Meeting 2016 Chicago, Illinois June 3-7, 2016

Highlights from the American Society of Clinical Oncology Annual Meeting (ASCO), which took place June 3-7, 2016 in Chicago, are available in a newsletter published by Evidence-Based Oncology.

Download PDF: Exclusive Coverage of the American Society of Clinical Oncology Annual Meeting 2016 Chicago, Illinois June 3-7, 2016

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Exclusive Coverage of the American Society of Clinical Oncology Annual Meeting 2016 Chicago, Illinois June 3-7, 2016

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Exclusive Coverage of the American Society of Clinical Oncology Annual Meeting 2016 Chicago, Illinois June 3-7, 2016

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer